Physician profile
Prospero V Arante
NPI 1649272857
$694.49
in general payments reported to CMS, 2019-2025
11 companies · $74.42 in 2025
The $74.42 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.77 · 2020: $119 · 2021: $203 · 2022: $102 · 2023: $118 · 2024: $21.09 · 2025: $74.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $213.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $186.47 | 2022-2025 | |
| Glaxosmithkline, LLC. | $110.14 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $78.47 | 2019-2021 | |
| Abbvie INC. | $73.98 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $71.76 | 2020-2022 | |
| Lilly USA, LLC | $43.32 | 2021-2023 | Jardiance |
| Amarin Pharma, INC. | $36.01 | 2019-2020 | |
| Enterra Medical, INC. | $28.68 | 2023 | |
| Janssen Pharmaceuticals, INC | $28.39 | 2020-2021 | |
| Abbott Laboratories | $23.10 | 2022 | |
| Astellas Pharma US INC | $14.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prospero Arante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.